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a  b  s  t  r  a  c  t
INTRODUCTION:  Malignant  melanoma  of  the heel  is  a  rare  melanoma  subtype  with  incidence  rates
that  reﬂect  the  complex  relationship  between  sun  exposure  at  certain  geographic  locations,  individ-
ual  melanin  levels  and  overall  melanoma  risk.  It  is oftentimes  characterized  by  poor  prognosis  because  of
delays in  presentation  resulting  in  longitudinal  tumor  invasion,  lymph  node  involvement  and  metastasis.
PRESENTATION  OF  CASE:  A  59-year-old  woman  was  admitted  to the  Eric Williams  Medical  Sciences  Com-
plex, Trinidad  and  Tobago  with  a  5 mm  pruritic  lesion  on  her left  heel.  At presentation,  the  lesion  was
asymmetric  with  border  irregularities,  color  heterogeneity,  with  dynamics  in elevation  and  overall  size.
She was  subsequently  diagnosed  with  malignant  melanoma  with  left inguinal  lymphadenopathy.  A sin-
gle  stage  wide  local  excision  (WLE)  of  the  left heel  lesion  with  a split-thickness  skin  graft  (STSG)  and  a  left
inguinal  lymphadenectomy  were performed.  Dacarbazine  (Bayer)  was  administered  post  operatively.
DISCUSSION:  Globally,  the  incidence  of malignant  melanoma  is  rapidly  increasing,  particularly,  in coun-
tries  like Trinidad  and  Tobago  with  a signiﬁcant  population  of non-fair  skinned  individuals.  There  is need
for strategic  initiatives  to  increase  patient  adherence  in these  populations.
CONCLUSION:  The  rarity  of  malignant  heel  melanomas  heightens  the need  for increased  patient  awareness
and  greater  clinical  surveillance  to ensure  early  diagnosis  and  treatment.
©  2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The incidence of malignant nodular melanoma is rare. Most
cases (almost 85%) occur in developed countries, where melanoma
ranks as the sixth most frequently diagnosed cancer overall [1].
Increased awareness and early diagnosis provides the framework
for improved prognosis and survival rates.
Generally, melanoma initiates with the development of either
dysplastic or benign nevi which advances to a radial growth phase
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marked by lateral spread with localization to the epidermis. Tran-
sition to the vertical growth phase is marked by invasion into the
dermis, subcutaneous tissue and upper epidermis, driven by cells
that are anchorage and growth factor independent. The most clin-
ically informative metric for this phase is the Breslow thickness
which provides a measure of the thickness of the tumor from the
upper layer of the epidermis to the depth of invasion.
To the best of our knowledge, this is the ﬁrst reported case report
of malignant melanoma of the heel among non-fair skinned indi-
viduals in the past 40 years. Given that melanomas are rare at this
latitude, it is therefore important to report this case and the cur-
rent clinical and surgical management approaches. This case report
was prepared in conformity with the Surgical CAse REport (SCARE)
guidelines which provides a framework for accuracy in surgical case
reports [2].
2. Case report
We  present the case of a 59-year-old female who  was  evaluated
at the Eric Williams Medical Sciences Complex (EWMSC), Trinidad
http://dx.doi.org/10.1016/j.ijscr.2016.11.047
2210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. A 59-year-old female with malignant melanoma. (A). Preoperative assessment of left heel lesion showing (3 cm × 3 cm) area of hyperpigmentation with color variation,
ill-deﬁned boarders and variation in symmetry, April 2014. (B). A clinical reoccurrence of the left heel lesion in September 2016 with multiple foci of raised, hyper pigmented
lesions  scattered throughout the distal third of the left leg and foot. The previous excision site with split-thickness skin graft (STSG) is noted at the posterior aspect of the
heel.
and Tobago (TT) for malignant melanoma of the heel. The patient
was of mixed ancestry (African and Indian), moderately obese (BMI
– 30.6 kg/m2), and without any family history of cancer. She ﬁrst
consulted a general practitioner then presented at the EWMSC  2
years later with a 5 mm left heel pruritic lesion, which ﬁt the clinical
presentation of the “ABCD rule” [3] in that it exhibited Asymmetry,
Border irregularities, Color heterogeneity, and Dynamics in col-
ors, elevation, and size (Fig. 1A). The patient recalled that over the
preceding 10-year period, the lesion increased in size and was occa-
sionally painful, with no bleeding. Previously, she had an unrelated
bilateral tubal ligation and prior treatment with paroxetine (Glax-
oSmithKline) for anxiety. She reported excess exposure to sunlight,
with no other skin conditions.
She had a left heel punch biopsy to rule out malignant
melanoma. The ensuing histopathology report detailed that sec-
tions of the skin showed a papillomatoses surface proﬁle with
Fig. 2. (A, B). Nevus cells. (A). Type A. Magniﬁcation 4× and (B). Type B nevus cells demonstrating Schwannian differentiation. Magniﬁcation,10×. (C, D). Microscopic images
(H&E)  of malignant melanoma. (C). At low magniﬁcation (40×), the tumor is noted to comprise nests and sheets of pigmented cells inﬁltrating deep into the dermis. Foci of
nests  of intra epidermal tumor epidermal nests are also seen (→). (D). Higher magniﬁcation (200×) highlights the atypical tumor cells with prominent nucleoli and “dusty”
intracytoplasmic melanin pigment. H & E staining on all panels.
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Fig. 3. Intra and postoperative images (A). Intraoperative photograph of left inguinal region after regional lymphadenectomy with exposed femoral artery. Sartorius muscle
is  seen detached from the anterior superior Iliac spine in preparation for transposition of the muscle ﬂap. (B). Transposed sartorius muscle ﬂap covering femoral artery (C).
Postoperative excision of left heel lesion showing depth and width of excision before split-thickness skin graft (STSG).
expansion of the dermis by nests and theques of Type A and
Type B nevus cells, which demonstrated schwannian differenti-
ation towards the base of the lesion. Junctional nests were also
identiﬁed at the tips of elongated rete. With no melanocytic atypia
recognized, it was determined that the ﬁndings were consistent
with a junctional melanocytic nevus (Fig. 2A, B). Four months later,
she had a wide local excision (WLE) and full thickness skin graft
to the heel lesion with continued care arranged at the out-patient
clinic. The surgical site was  examined at 1-week and 3-months post
excision and appeared to be healing satisfactorily. A year later at her
clinic appointment, a reoccurrence of the lesion was  noted but she
declined further surgical intervention. A month later, during a visit
to the plastic surgery out-patient clinic she complained of a painless
swelling to the left inguinal area. A 4.0 cm solitary lymph node was
identiﬁed in the left inguinal region and was noted to be well cir-
cumscribed, nodular, mobile and tender, with mild erythema on the
overlying skin. The patient was counselled to continue follow-up
with the aim of elective surgical intervention.
A multi-disciplinary team representing general surgery, oncol-
ogy, plastic surgery, and radiology was assembled to manage her
case. A decision was  made, with curative intent to perform a sin-
gle stage wide local excision (WLE) of the left heel lesion with a
Fig. 4. (A). Lymph node architecture completely effaced by heavily pigmented tumor cells. H&E staining. Magniﬁcation, 4×. (B). and (C). Subcapsular and sinusoidal location
of  pigmented tumor cells. Magniﬁcation, 4×. (D, E). Characteristic pleomorphic tumor cells exhibiting vesicular chromatin and prominent eosinophilic macronucleoli. (D).
Magniﬁcation, 40×.  (E). Magniﬁcation, 10×.
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Fig. 5. Patient chest radiographs. (A). Normal posterioranterior chest radiograph from January 2016. (B). posterioranterior chest radiograph 8 months later. Red arrows,
multiple bilateral pulmonary nodules with no calciﬁcation or cavitation consistent with pulmonary metastases; blue arrow, ﬂuid in right horizontal ﬁssure; green arrow,
loculated right pleural effusion; yellow arrows, cardiomegaly; purple arrows, right mid  and lower zone consolidation with some obscuration of the right heart border. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
split-thickness skin graft (STSG) and a left inguinal lymphadenec-
tomy with Sartorius transposition (ST) over the femoral vessels. Her
preoperative assessments consisting of blood investigations, chest
x-ray, electrocardiogram, and computed tomography (CT) of her
abdomen, pelvis and brain were unremarkable. A month later, the
patient had a lymphadenectomy and a STSG without post-operative
complications (Fig. 3A, B, C). She was advised on to start adjuvant
therapy immediately but she delayed for 5 months before com-
mencing on Dacarbazine (Bayer) (5 cycles). A month later, on her
outpatient follow up at St. James Cancer Treatment Center, TT she
had a Grade 0 on the Eastern Cooperative Oncology Group (ECOG)
Scale of Performance Status [4].
Three samples from the heel and one from the left inguinal
lymph node were examined by the histopathologist. The section
from the lymph node showed an effaced architecture of heavily
pigmented cells in the subcapsular, sinusoidal and focal capsular
pattern with the heavily pigmented cells obscuring the nuclear
features (Fig. 4A–C). There were a few areas that showed pleo-
morphic tumor cells with vesicular chromatin and prominent
eosinophilic macronucleoli (Fig. 4D, E). The extracapsular, extra
nodal soft tissue and surgical excised margins were negative for
tumor deposits. The histological ﬁndings from the left inguinal
lymph node were consistent with metastatic malignant melanoma.
Specimens from the left heel skin (wide local excision), superior
heel excision and inferior heel excision yielded similar ﬁndings.
The Breslow [5] depth was 1.0 cm with Clark [6] anatomical level
V (invasion of subcutis) with a mitotic rate of 0.0/mm2. Guided by
standard pathologic assessments, the deep soft tissue and periph-
eral skin margin were negative at 0.5 cm and 1.0 cm away from the
tumor, respectively [7]. There was an absence of tumor inﬁltrating
lymphocytes, ulcerations, lymphovascular invasion and perineu-
ral invasion. The histopathological ﬁndings was  that of malignant
melanoma (Fig. 2C, D) at stage pT3a pN1a M0  according to the
American Joint Committee on Cancer system (AJCC) 7th edition
guidelines [8].
A follow up appointment, six months later revealed the presence
of numerous hyper-pigmented lesions scattered throughout her
left leg and foot with characteristics similar to that of her initial pre-
sentation (Fig. 1B). Arrangements were made to biopsy the existing
lesions for histological conﬁrmation of reoccurrence with the pos-
sibility of isolated limb perfusion. A month later, she was admitted
to EWMSC complaining of shortness of breath and lower back pain.
A chest X-ray showed multiple bilateral pulmonary nodules with
no calciﬁcation or cavitation consistent with pulmonary metastases
(Fig. 5A, B). In addition to her hypertension medications, she was
placed on Dexamethasone (Decadron, Merck), Nexium (Esomepra-
zole, AstraZeneca) Morphine, Disprol (Paracetamol) and Tramacet
(Janssen). At the time of the manuscript preparation, the patient
was provided with an oxygen tank and discharged.
An extensive medical literature search conducted using
PubMed/MEDLINE and Embase databases found two case reports
detailing malignant melanoma of the heel among non-fair skinned
individuals. One study was  a review of nine cases of the malignant
melanoma of the heel in Puerto Rico (1948–1972) and the other
paper from 1972 was  not retrievable [9,10].
3. Discussion
For the period 1995–2009, melanomas of the heel, lower limb
and hips constituted 0.11% of the reported incident cancer cases in
TT (personal communication with the TT Cancer Registry). Globally,
the incidence of malignant melanoma is rapidly increasing, partic-
ularly, in countries that have had historically low rates [11,12]. In
fact, lung cancer in women is the only neoplasm that is growing
at a faster rate globally [11]. This shift warrants a greater focus
on screening, early diagnosis and expanded precision treatment
options among non-fair skin individuals. Many of the genetic events
accompanying the development of melanoma have been character-
ized. It is important that developing countries, like TT build capacity
for these genomic proﬁling and precision medicine approaches to
guide treatment algorithms and reduce the cancer burden [13].
Like many developing countries, TT does not have extensive
nuclear medicine capabilities including positron emission tomog-
raphy/computed tomography (PET/CT) systems. As the shift in the
morbidity and mortality burden occurs towards chronic and non-
communicable diseases, there is greater need to include PET/CT in
the diagnostic arsenal.
Despite the fact that TT offers free universal health care and that
melanoma is widely considered to be one of the more preventable
cancer types, the patient did not seek treatment for 10 years
post initial observation of skin change. The lesions of the major-
ity of patients with cutaneous melanoma were initially detected
by the patient themselves on self-examination (44%) or by their
spouse (18.6%) with primary care provider (PCP) detection account-
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ing for 25% [14,15]. It is therefore important to emphasize public
awareness and PCP awareness of the “ABCD Rule” to ensure ear-
lier detection of cutaneous melanomas [3,15,16]. While screening
programs have utility, they can be an economic burden in develop-
ing countries with low melanoma incidence. One approach utilizes
innovative information technology and mobile phone usage in an
application described as mobile teledermoscopy [17]. While it is not
a substitute for a physical consultation with a PCP, it provides a cost
effective approach to early detection of melanomas in patients who
might otherwise go undiagnosed and in regions where a screening
program is not economically feasible.
In the management of this case, there were numerous instances
where the patient failed to adhere to the treatment protocol. While
some potential strategies have been reviewed elsewhere [18], there
is need for research on patient non-adherence in developing coun-
tries as well as country speciﬁc strategies to increase adherence.
4. Conclusion
Given the increasing rate of malignant melanomas among non-
fair skin individuals, this case highlights the need for increased
public awareness, early diagnosis and the importance of clinical
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